Timing and duration of use of GnRH antagonist down-regulation for IVF/ICSI cycles have no impact on oocyte quality or pregnancy outcomes

Journal of Assisted Reproduction and Genetics

Volumn 25, Issue 5, 2008, Pages 177-181

  Detti, Laura ^a   Ambler, Dana R ^a   Yelian, Frank D ^a   Kruger, Michael L ^a   Diamond, Michael P ^a   Puscheck, Elizabeth E ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

GnRH antagonist; Implantation; IVF ICSI; Oocyte; Pregnancy

Indexed keywords

ESTRADIOL; GANIRELIX; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FERTILIZATION; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; OOCYTE; PREGNANCY; PRIORITY JOURNAL;

ADULT; COHORT STUDIES; DOWN-REGULATION; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; MIDDLE AGED; OOCYTES; PREGNANCY; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 44549087994     PISSN: 10580468     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10815-008-9217-2     Document Type: Article

References (15)

1. Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT, Schoolcraft W, Shapiro DB, North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001;75:38-45.
2. Borm G, Mannaerts B. Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 2000;15:1490-8.
3. Lindheim SR, Morales AJ. GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles. Hum Reprod 2003;18:2048-51.
4. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotropin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006;3:CD001750.
5. Acevedo B, Sanchez M, Gomez JL, Cuadros J, Ricciarelli E, Hernandez ER. Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles. Fertil Steril 2004;82:343-7.
6. Cedrin-Durnerin I, Grange-Dujardin D, Laffy A, Parneix I, Massin N, Galey J, Theron L, Wolf JP, Conord C, Clement P, Jayot S, Hugues JN. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2004;19:1979-84.
7. Hernandez ER. Embryo implantation and GnRH-antagonists. Hum Reprod 2000;15:1211-6.
8. Duijkers IJ, Klipping C, Willemsen WN, Krone D, Schneider E, Niebch G, Hermann R. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotropin-releasing hormone antagonist cetrorelix in healthy female volunteers. Hum Reprod 1998;13:2392-8.
9. Murdoch WJ. Immunolocalization of a gonadotropin-releasing hormone receptor site in murine endometrium that mediates apoptosis. Cell Tissue Res 1995;282:527-9.
10. Raga F, Casañ EM, Kruessel JS, Wen Y, Huang HY, Nezhat C, Polan ML. Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biol Reprod 1998;59:661-9.
11. Grundker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B, Emons G. Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 2004;151:141-9.
12. Ruan HC, Zhu XH, Luo Q, Liu AX, Qian YL, Zhou CY, Jin F, Huang HF, Sheng JZ. Ovarian stimulation with GnRH agonist, but not GnRH antagonist, partially restores the expression of endometrial integrin beta3 and leukaemia-inhibitory factor and improves uterine receptivity in mice. Hum Reprod 2006;21:2521-9.
13. Xavier P, Gamboa C, Calejo L, Silva J, Stevenson D, Nunes A, Martinez-de-Oliveira J. A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy. Eur J Obstet Gynecol Reprod Biol 2005;120:185-9.
14. Kolibianakis E, Bourgain C, Albano C, Osmanagaoglu K, Smitz J, Van Steirteghem A, Devroey P. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril 2002;78:1025-9.
15. Papanikolaou EG, Camus M, Fatemi HM, Tournaye H, Verheyen G, Van Steirteghem A, Devroey P. Early pregnancy loss is significantly higher after day 3 single embryo transfer than after day 5 single blastocyst transfer in GnRH antagonist stimulated IVF cycles. Reprod Biomed Online 2006;12:60-5.